ESMO
ESMO

Abstract Submission is Open for ESMO Targeted Anticancer Therapies Congress 2026

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Present your findings to an international audience of academics, scientists, and leaders from the pharmaceutical industry, at one of the most important events in cancer drug discovery.

New this year: Trial in Progress (TiP) abstracts in all phases of clinical research may be submitted.

Deadline: 16 December 2025 Submit your abstract.

Submit your abstract.”

Abstract Submission is Open for ESMO Targeted Anticancer Therapies Congress 2026

More Posts Featuring ESMO.